Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.5%

3 terminated/withdrawn out of 198 trials

Success Rate

92.7%

+6.2% vs industry average

Late-Stage Pipeline

12%

24 trials in Phase 3/4

Results Transparency

8%

3 of 38 completed trials have results

Key Signals

46 recruiting3 with results

Enrollment Performance

Analytics

N/A
56(53.3%)
Phase 2
23(21.9%)
Phase 3
14(13.3%)
Phase 4
10(9.5%)
Phase 1
2(1.9%)
105Total
N/A(56)
Phase 2(23)
Phase 3(14)
Phase 4(10)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (198)

Showing 20 of 198 trials
NCT07565350Not ApplicableRecruiting

Local Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts

Role: lead

NCT07557914Phase 2Not Yet Recruiting

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

Role: collaborator

NCT06597227Not ApplicableRecruiting

Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Role: collaborator

NCT07534865Not ApplicableRecruiting

Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts

Role: lead

NCT07533825Not ApplicableEnrolling By Invitation

Laparoscopic Staging for Stage III Gastric Cancer

Role: collaborator

NCT06084819Phase 2Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT07503652Phase 4Recruiting

Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

Role: lead

NCT03657732Recruiting

The Chinese Familial Alzheimer's Network

Role: collaborator

NCT03653156Recruiting

China Cognition and Aging Study

Role: collaborator

NCT07483359Phase 2Not Yet Recruiting

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Role: lead

NCT07480525Not ApplicableNot Yet Recruiting

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

Role: collaborator

NCT07476898Phase 3Not Yet Recruiting

Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window

Role: lead

NCT07459296Phase 3Recruiting

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Role: collaborator

NCT07463300Recruiting

A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging

Role: collaborator

NCT07452406Not ApplicableNot Yet Recruiting

Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients

Role: collaborator

NCT07454941Enrolling By Invitation

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

Role: collaborator

NCT07449858Active Not Recruiting

18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC

Role: collaborator

NCT05888350Not ApplicableCompleted

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

Role: collaborator

NCT07402525Not ApplicableRecruiting

Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

Role: collaborator

NCT06631326Completed

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

Role: lead